China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with Pheon Therapeutics (Pheon), a leading UK-based antibody-drug conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. According to the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary RenMice platforms. Biocytogen will receive an upfront payment and is eligible for development and commercial milestone payments, as well as single-digit royalties on net sales.
Biocytogen’s RenMice Platforms and Their Benefits
Biocytogen’s proprietary RenMice platforms feature the complete replacement of human antibody variable genes in situ. These platforms, combined with target knock-out strategy, empower the generation of fully human antibodies with low immunogenicity, great diversity, species cross-reactivity, high affinity, and good developability. The RenMice platforms and derived antibodies have been recognized by many renowned biotech and biopharmaceutical companies, highlighting their potential in advancing antibody development.
Expanding Pheon’s ADC Pipeline
The new agreement expands Pheon’s ADC pipeline, which boasts first-in-class and best-in-class ADCs to meet significant unmet clinical needs in oncology. Pheon launched in March 2022 with a USD68 million Series A financing led by a strong leadership team of specialists in targeted oncology therapies and ADCs. This collaboration with Biocytogen is a strategic move that aligns with Pheon’s mission to develop innovative ADCs for the treatment of various cancers.-Fineline Info & Tech
